Name: 글로벌 시장 동향
SKU: MD7803
Availability: InStock

보고서 요약(국문)

개요
전 세계 에어로졸 전달 장치 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
에어로졸은 기체(일반적으로 공기)에 고체 또는 액체 입자가 현탁된 시스템입니다. 이를 통해 약물을 폐를 통해 혈류로 직접 전달할 수 있으며, 정맥 주사의 합병증(통증 및 주사 부위 감염 등)을 예방할 수 있습니다. 이 기술은 주로 천식을 포함한 폐 질환 치료제 투여에 사용되지만, 다른 치료법에도 유용할 수 있습니다.
시장 동향: 성장 동인 및 제약 요인
호흡기 질환 유병률 증가
호흡기 질환 유병률의 증가는 예측 기간 동안 전 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 세계보건기구(WHO)의 2021년 자료에 따르면, 만성폐쇄성폐질환(COPD)은 전 세계적으로 세 번째로 흔한 사망 원인으로, 2020년에 323만 명의 사망자를 발생시켰습니다. 이 사망자의 80% 이상이 저소득 및 중소득 국가(LMIC)에서 발생했습니다.
또한, 미국 천식 및 알레르기 재단(Asthma and Allergy Foundation of America)의 2021년 3월 자료에 따르면, 미국인 13명 중 1명꼴로 천식을 앓고 있으며, 이는 약 2,500만 명에 해당합니다. 천식은 어린이, 성인, 노인을 포함한 모든 연령층에서 질병 발생의 주요 원인 중 하나입니다. 같은 자료에 따르면, 약 500만 명의 미국 어린이가 천식을 앓고 있습니다.
더 나아가, 기술 발전, 연구 활동 증가, 투자 확대, 그리고 인식 제고는 예측 기간 동안 세계 시장 성장을 촉진하는 추가적인 요인들입니다.

제품 리콜
시장에서 증가하는 제품 리콜 사례는 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다. 예를 들어, 시플라 리미티드(Cipla Limited)의 완전 자회사인 시플라 USA(Cipla USA Inc.)는 미국 식품의약국(FDA)의 인지 하에 2021년 11월에 제조된 알부테롤 황산염 흡입 에어로졸 90mcg(200회 정량 흡입) 6개 배치를 소비자 수준에서 자발적으로 회수했습니다. 또한, 엄격한 규제 기관과 높은 개발 비용은 예측 기간 동안 세계 시장 성장을 저해하는 추가적인 요인입니다.
세분화 분석
세계 에어로졸 전달 장치 시장은 제품, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.
정량 흡입기가 시장을 주도할 것으로 예상됨
규제 기관의 정량 흡입기 승인이 증가함에 따라, 이 부문은 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2021년 10월 BreatheSuite는 기존 흡입기를 천식 및 COPD 환자를 위한 스마트 흡입기로 바꿔주는 Metered-Dose Inhaler V1 장치에 대해 FDA로부터 510(k) 승인을 받았습니다. 또한, 2023년 7월 루핀의 자회사인 Hormosan Pharma GmbH는 독일에서 천식 및 만성 폐쇄성 폐질환(COPD) 치료를 위한 가압식 정량 흡입기를 출시했습니다.
지역 분석
북미 지역이 세계 시장을 주도할 것으로 예상됨
북미 지역의 승인 증가로 인해 해당 지역은 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2023년 7월 다국적 의료 기업인 비아트리스(Viatris Inc.)와 킨데바 드럭 딜리버리(Kindeva Drug Delivery)는 아스트라제네카의 심비코트(Symbicort)의 최초 제네릭 버전인 브레이나(Breyna, 부데소니드 및 포모테롤 푸마르산염 이수화물) 흡입 에어로졸을 출시했으며, 미국 식품의약국(FDA)으로부터 약식 신약 신청(ANDA) 승인을 받았습니다. 또한, 2020년 2월 미국 식품의약국(FDA)은 가역적 폐쇄성 기도 질환이 있는 4세 이상 환자의 기관지 경련 치료 또는 예방 및 4세 이상 환자의 운동 유발성 기관지 경련 예방을 위한 최초 제네릭 프로에어 HFA(ProAir HFA, 알부테롤 황산염) 흡입 에어로졸을 승인했습니다.
COVID-19 영향 분석
SARS-CoV-2는 폐를 직접 공격하여 폐 손상을 유발하므로, 흡입제를 이용한 COVID-19 치료는 경구/비경구 투여에 비해 여러 가지 이점을 제공합니다. 흡입 약물 전달은 특히 폐 시스템에서 더 높은 약물 농도를 전달합니다. 이는 전신 부작용을 줄이고 빠른 임상 반응을 유도하므로, 팬데믹 기간 동안 에어로졸 전달 장치에 대한 수요와 투자가 증가하여 세계 시장에 긍정적인 영향을 미쳤습니다.
시장 세분화
제품별
• 건조 분말 흡입기
• 정량 분무 흡입기
• 네뷸라이저
적용 분야별
• 천식
• 만성 폐쇄성 폐질환(COPD)
• 낭포성 섬유증
• 비호흡기 질환
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2022년 6월, 유나이티드 테라퓨틱스(United Therapeutics Corporation)는 폐동맥 고혈압 및 간질성 폐질환 관련 폐고혈압 치료용 흡입 분말인 티바소(Tyvaso) DPI에 대해 미국 식품의약국(FDA)의 승인을 획득했습니다. 질병.

• 2023년 1월, 아스트라제네카는 미국 식품의약국(FDA)으로부터 에어수프라(알부테롤 및 부데소니드) 흡입 에어로졸에 대한 승인을 받았습니다. 에어수프라는 18세 이상 성인의 천식 악화 위험을 줄이는 데 도움을 줍니다.
경쟁 환경
시장의 주요 글로벌 업체로는 3M, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Pfizer Inc, Merck & Co., Inc., Genentech USA, Inc. 및 MannKind Corporation 등이 있습니다.

보고서 구매 이유

• 제품, 적용 분야, 유통 채널 및 지역별 글로벌 에어로졸 전달 장치 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위해.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해.

• 모든 세그먼트를 포함한 에어로졸 전달 장치 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 에어로졸 전달 장치 시장 보고서는 약 62개의 표, 58개의 그림, 184페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global aerosol delivery device market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Aerosol is a suspension system of solid or liquid particles in a gas, typically air. It allows for medication to be delivered directly to the bloodstream through the lungs, without the complications of an IV, such as pain and injection site infection. This technique is primarily used for dosing medication for lung conditions, including asthma, but it may be beneficial for other therapies as well.
Market Dynamics: Drivers & Restraints
Growing Prevalence of Respiratory Diseases
The growing prevalence of respiratory diseases is expected to boost the global market growth during the forecast period. For instance, according to the World Health Organization (WHO) 2021 factsheet, COPD was among the third-leading reason of death globally, inducing 3.23 million casualties in 2020. More than 80% of these casualties happened in low and middle-income countries (LMIC).
Also, according to the Asthma and Allergy Foundation of America in March 2021, approximately 1 in 13 Americans had asthma, which was approximately 25 million individuals. Asthma is among the biggest contributors to this formation, involving children, adults, and geriatric individuals. The same reference remarked that almost 5 million American children had asthma.
Furthermore, the technological advancements, rise in research activities, increaseing investments and growing awareness are among the other additional factors boosting the global market growth during the forecast period.
Product Recalls
The increasing incidences of product recalls from market are expected to hamper the global market growth during the forecast period. for instance, Cipla Limited's wholly-owned associate, Cipla USA Inc., willingly recalled six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) manufactured in November 2021 to the consumer level with the knowledge of the U.S. Food and Drug Administration. Furthermore, stringent regulatory bodies, and high development costs are other additional factors hampering the global market growth during the forecast period.
Segment Analysis
The global aerosol delivery device market is segmented based on product, application, distribution channel and region.
Metered Dose Inhalers are Expected to Dominate Market
Owing to the increasing authorizations from the regulatory bodies for metered dose inhalers, the segment is expected to dominate the global market during the forecast period. For instance, in October 2021, BreatheSuite obtained 510(k) authorization from the FDA for its Metered-Dose Inhaler V1 device, which turns existing inhalers into smart inhalers for individuals with asthma and COPD. Moreover, in July 2023, Lupin's subsidiary unit Hormosan Pharma GmbH introduced a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Germany.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increasing approvals in North America the region is expected to dominate the global market during the forecast period. For instance, in July 2023, Viatris Inc., a multinational healthcare corporation, and Kindeva Drug Delivery introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the foremost generic version of AstraZeneca's Symbicort with an Abbreviated New Drug Application (ANDA) authorized by the U.S. Food and Drug Administration (FDA). Moreover, in February 2020, The US Food and Drug Administration (FDA) authorized the foremost generic of ProAir HFA (albuterol sulfate) inhalation aerosol to treat or prevent bronchospasm in individuals of four years of age and older with reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients four years of age and older.
COVID-19 Impact Analysis
As SARS-CoV-2 directly targets the lungs and initiates lung damage, treating COVID-19 with inhalants presents multiple benefits over the enteral/parenteral administration. Inhaled drug delivery delivers higher drug concentrations, particularly in the pulmonary system. This allows the lessening of systemic side effects and delivers a quick clinical reaction, therefore, the pandemic has led to an increase in the demand for and investments in aerosol delivery devices, positively impacting the global market during the pandemic.
Market Segmentation
By Product
• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers
By Applications
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Non-Respiratory Diseases
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In June 2022, United Therapeutics Corporation obtained FDA authorization for its Tyvaso DPI, an inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension linked with interstitial lung diseases.
• In January 2023, AstraZeneca obtained authorization from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra strives to decrease the threat of asthma exacerbations in people aged 18 years and older.
Competitive Landscape
The major global players in the market include 3M Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Pfizer Inc, Merck & Co., Inc., Genentech USA, Inc. and MannKind Corporation among others.
Why Purchase the Report?
• To visualize the global aerosol delivery device market segmentation based on product, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aerosol delivery device market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global aerosol delivery device market report would provide approximately 62 tables, 58 figures and 184 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence of Respiratory Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Product Recalls
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Pricing Analysis
5.3. Regulatory Analysis
5.4. Patent Analysis
5.5. Product Trend
5.6. Unmet Need
5.7. Epidemiology Analysis
5.8. SWOT Analysis
5.9. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
7.1.2. Market Attractiveness Index, By Product
7.2. Dry Powder Inhalers*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Metered Dose Inhalers
7.4. Nebulizers
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Asthma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chronic Obstructive Pulmonary Disease (COPD)
8.4. Cystic Fibrosis
8.5. Non-Respiratory Diseases
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. 3M Company, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. GlaxoSmithKline plc
12.3. Teva Pharmaceutical Industries Ltd., Inc.
12.4. Cipla Inc.
12.5. Boehringer Ingelheim International GmbH
12.6. AstraZeneca,
12.7. Pfizer Inc
12.8. Merck & Co., Inc.
12.9. Genentech USA, Inc.
12.10. MannKind Corporation
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

3M Company, Inc., 4.	Key Developments, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Inc., Cipla Inc., Boehringer Ingelheim International GmbH, AstraZeneca,, Pfizer Inc, Merck & Co., Inc., Genentech USA, Inc., MannKind Corporation

표 목록 (Tables)

List of Tables

Table 1 Global Aerosol Delivery Device Market Value, By Product, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Aerosol Delivery Device Market Value, By Applications, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Aerosol Delivery Device Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Aerosol Delivery Device Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Aerosol Delivery Device Market Value, By Product, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Aerosol Delivery Device Market Value, By Product, 2022-2031 (US$ Million)

Table 7 Global Aerosol Delivery Device Market Value, By Applications, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Aerosol Delivery Device Market Value, By Applications, 2022-2031 (US$ Million)

Table 9 Global Aerosol Delivery Device Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Aerosol Delivery Device Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Aerosol Delivery Device Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Aerosol Delivery Device Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Aerosol Delivery Device Market Value, By Product, 2022-2031 (US$ Million)

Table 14 North America Aerosol Delivery Device Market Value, By Applications, 2022-2031 (US$ Million)

Table 15 North America Aerosol Delivery Device Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Aerosol Delivery Device Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Aerosol Delivery Device Market Value, By Product, 2022-2031 (US$ Million)

Table 18 South America Aerosol Delivery Device Market Value, By Applications, 2022-2031 (US$ Million)

Table 19 South America Aerosol Delivery Device Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Aerosol Delivery Device Market Value, By 0, 2022-2031 (US$ Million)

Table 21 South America Aerosol Delivery Device Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Europe Aerosol Delivery Device Market Value, By Product, 2022-2031 (US$ Million)

Table 23 Europe Aerosol Delivery Device Market Value, By Applications, 2022-2031 (US$ Million)

Table 24 Europe Aerosol Delivery Device Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 Europe Aerosol Delivery Device Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Aerosol Delivery Device Market Value, By Product, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Aerosol Delivery Device Market Value, By Applications, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Aerosol Delivery Device Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 29 Asia-Pacific Aerosol Delivery Device Market Value, By Country, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Aerosol Delivery Device Market Value, By Product, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Aerosol Delivery Device Market Value, By Applications, 2022-2031 (US$ Million)

Table 32 Middle East & Africa Aerosol Delivery Device Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 33 3M Company, Inc.: Overview

Table 34 3M Company, Inc.: Product Portfolio

Table 35 3M Company, Inc.: Key Developments

Table 36 GlaxoSmithKline plc: Overview

Table 37 GlaxoSmithKline plc: Product Portfolio

Table 38 GlaxoSmithKline plc: Key Developments

Table 39 Teva Pharmaceutical Industries Ltd., Inc.: Overview

Table 40 Teva Pharmaceutical Industries Ltd., Inc.: Product Portfolio

Table 41 Teva Pharmaceutical Industries Ltd., Inc.: Key Developments

Table 42 Cipla Inc.: Overview

Table 43 Cipla Inc.: Product Portfolio

Table 44 Cipla Inc.: Key Developments

Table 45 Boehringer Ingelheim International GmbH: Overview

Table 46 Boehringer Ingelheim International GmbH: Product Portfolio

Table 47 Boehringer Ingelheim International GmbH: Key Developments

Table 48 AstraZeneca: Overview

Table 49 AstraZeneca: Product Portfolio

Table 50 AstraZeneca: Key Developments

Table 51 Pfizer Inc: Overview

Table 52 Pfizer Inc: Product Portfolio

Table 53 Pfizer Inc: Key Developments

Table 54 Merck & Co., Inc.: Overview

Table 55 Merck & Co., Inc.: Product Portfolio

Table 56 Merck & Co., Inc.: Key Developments

Table 57 Genentech USA, Inc.: Overview

Table 58 Genentech USA, Inc.: Product Portfolio

Table 59 Genentech USA, Inc.: Key Developments

Table 60 MannKind Corporation: Overview

Table 61 MannKind Corporation: Product Portfolio

Table 62 MannKind Corporation: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 2 Global Aerosol Delivery Device Market Share, By Product, 2022 & 2031 (%)

Figure 3 Global Aerosol Delivery Device Market Share, By Applications, 2022 & 2031 (%)

Figure 4 Global Aerosol Delivery Device Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Aerosol Delivery Device Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Aerosol Delivery Device Market Y-o-Y Growth, By Product, 2022-2031 (%)

Figure 7 Dry Powder Inhalers Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 8 Metered Dose Inhalers Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 9 Nebulizers Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 10 Global Aerosol Delivery Device Market Y-o-Y Growth, By Applications, 2022-2031 (%)

Figure 11 Asthma Applications in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 12 Chronic Obstructive Pulmonary Disease (COPD) Applications in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 13 Cystic Fibrosis Applications in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 14 Non-Respiratory Diseases Applications in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 15 Global Aerosol Delivery Device Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 16 Hospital Pharmacies Distribution Channel in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 17 Retail Pharmacies Distribution Channel in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 18 Online Pharmacies Distribution Channel in Global Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 19 Global Aerosol Delivery Device Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 20 North America Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 21 Asia-Pacific Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 22 Europe Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 23 South America Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 24 Middle East and Africa Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 25 North America Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 26 North America Aerosol Delivery Device Market Share, By Product, 2022 & 2031 (%)

Figure 27 North America Aerosol Delivery Device Market Share, By Applications, 2022 & 2031 (%)

Figure 28 North America Aerosol Delivery Device Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 29 North America Aerosol Delivery Device Market Share, By Country, 2022 & 2031 (%)

Figure 30 South America Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 31 South America Aerosol Delivery Device Market Share, By Product, 2022 & 2031 (%)

Figure 32 South America Aerosol Delivery Device Market Share, By Applications, 2022 & 2031 (%)

Figure 33 South America Aerosol Delivery Device Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 34 South America Aerosol Delivery Device Market Share, By Country, 2022 & 2031 (%)

Figure 35 Europe Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 36 Europe Aerosol Delivery Device Market Share, By Product, 2022 & 2031 (%)

Figure 37 Europe Aerosol Delivery Device Market Share, By Applications, 2022 & 2031 (%)

Figure 38 Europe Aerosol Delivery Device Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 39 Europe Aerosol Delivery Device Market Share, By Country, 2022 & 2031 (%)

Figure 40 Asia-Pacific Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 41 Asia-Pacific Aerosol Delivery Device Market Share, By Product, 2022 & 2031 (%)

Figure 42 Asia-Pacific Aerosol Delivery Device Market Share, By Applications, 2022 & 2031 (%)

Figure 43 Asia-Pacific Aerosol Delivery Device Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 44 Asia-Pacific Aerosol Delivery Device Market Share, By Country, 2022 & 2031 (%)

Figure 45 Middle East & Africa Aerosol Delivery Device Market Value, 2022-2031 (US$ Million)

Figure 46 Middle East & Africa Aerosol Delivery Device Market Share, By Product, 2022 & 2031 (%)

Figure 47 Middle East & Africa Aerosol Delivery Device Market Share, By Applications, 2022 & 2031 (%)

Figure 48 Middle East & Africa Aerosol Delivery Device Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 49 3M Company, Inc.: Financials

Figure 50 GlaxoSmithKline plc: Financials

Figure 51 Teva Pharmaceutical Industries Ltd., Inc.: Financials

Figure 52 Cipla Inc.: Financials

Figure 53 Boehringer Ingelheim International GmbH: Financials

Figure 54 AstraZeneca: Financials

Figure 55 Pfizer Inc: Financials

Figure 56 Merck & Co., Inc.: Financials

Figure 57 Genentech USA, Inc.: Financials

Figure 58 MannKind Corporation: Financials

글로벌 에어로졸 전달 장치 시장 – 2023-2030

Global Aerosol Delivery Device Market - 2023-2030